Nanocarrier‐delivered small interfering RNA for chemoresistant ovarian cancer therapy

2021 ◽  
Author(s):  
Mingyuan Zou ◽  
Yue Du ◽  
Ruizhen Liu ◽  
Zeliang Zheng ◽  
Jian Xu
Keyword(s):  
Ovarian Cancer ◽  
Cancer Therapy ◽  
Small Interfering Rna ◽  
Interfering Rna ◽  
Chemoresistant Ovarian Cancer

A Nanoparticle Carrier for Co-Delivery of Gemcitabine and Small Interfering RNA in Pancreatic Cancer Therapy

2016 ◽  
Vol 12 (8) ◽  
pp. 1654-1666 ◽  
Author(s):  
Jiajia Li ◽  
Yinting Chen ◽  
Linjuan Zeng ◽  
Guoda Lian ◽  
Shaojie Chen ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Cancer Therapy ◽  
Small Interfering Rna ◽  
Pancreatic Cancer Therapy ◽  
Interfering Rna

scholarly journals Switching the intracellular pathway and enhancing the therapeutic efficacy of small interfering RNA by auroliposome

2020 ◽  
Vol 6 (30) ◽  
pp. eaba5379 ◽  
Author(s):  
Md. Nazir Hossen ◽  
Lin Wang ◽  
Harisha R. Chinthalapally ◽  
Joe D. Robertson ◽  
Kar-Ming Fung ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Gold Nanoparticles ◽  
Gene Silencing ◽  
Small Interfering Rna ◽  
Sirna Delivery ◽  
Delivery Systems ◽  
Ovarian Cancer Cells ◽  
Interfering Rna

Gene silencing using small-interfering RNA (siRNA) is a viable therapeutic approach; however, the lack of effective delivery systems limits its clinical translation. Herein, we doped conventional siRNA-liposomal formulations with gold nanoparticles to create “auroliposomes,” which significantly enhanced gene silencing. We targeted MICU1, a novel glycolytic switch in ovarian cancer, and delivered MICU1-siRNA using three delivery systems—commercial transfection agents, conventional liposomes, and auroliposomes. Low-dose siRNA via transfection or conventional liposomes was ineffective for MICU1 silencing; however, in auroliposomes, the same dose gave >85% gene silencing. Efficacy was evident from both in vitro growth assays of ovarian cancer cells and in vivo tumor growth in human ovarian cell line—and patient-derived xenograft models. Incorporation of gold nanoparticles shifted intracellular uptake pathways such that liposomes avoided degradation within lysosomes. Auroliposomes were nontoxic to vital organs. Therefore, auroliposomes represent a novel siRNA delivery system with superior efficacy for multiple therapeutic applications.

Sign in / Sign up

Export Citation Format

Share Document